Medical treatment of hypertrophic cardiomyopathy - What do we know about it today?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F15%3A43909663" target="_blank" >RIV/00216208:11120/15:43909663 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.crvasa.2015.02.003" target="_blank" >http://dx.doi.org/10.1016/j.crvasa.2015.02.003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2015.02.003" target="_blank" >10.1016/j.crvasa.2015.02.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Medical treatment of hypertrophic cardiomyopathy - What do we know about it today?

Popis výsledku v původním jazyce

Beta-blockers represent a cornerstone of the treatment of symptomatic hypertrophic cardiomyopathy – they are the first-line therapy for obstructive and non-obstructive forms. Sympathetic modulation leads to the deceleration of heart rate at rest and after exertion, and unconvincingly to the improvement of left ventricular diastolic function and obstruction. Medications include also nondihydropyridine calcium channel blockers without significant vasodilatory properties, i.e. verapamil and diltiazem. Other medications used are class IA antiarrhythmic drugs – disopyramide or cibenzoline, which can be administered to patients with obstructive forms when first-line agents have not been effective. Amiodarone and diuretics can be used in special indications. Some other agents including statins are in the stage of clinical investigation.

Název v anglickém jazyce

Medical treatment of hypertrophic cardiomyopathy - What do we know about it today?

Popis výsledku anglicky

Beta-blockers represent a cornerstone of the treatment of symptomatic hypertrophic cardiomyopathy – they are the first-line therapy for obstructive and non-obstructive forms. Sympathetic modulation leads to the deceleration of heart rate at rest and after exertion, and unconvincingly to the improvement of left ventricular diastolic function and obstruction. Medications include also nondihydropyridine calcium channel blockers without significant vasodilatory properties, i.e. verapamil and diltiazem. Other medications used are class IA antiarrhythmic drugs – disopyramide or cibenzoline, which can be administered to patients with obstructive forms when first-line agents have not been effective. Amiodarone and diuretics can be used in special indications. Some other agents including statins are in the stage of clinical investigation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

"e219"-"e224"

Kód UT WoS článku

000409987500009

EID výsledku v databázi Scopus

2-s2.0-84931006435